CAB Spotlight - Vijaya Jori | Johns Hopkins University Baltimore-India Clinical Trials Unit

CAB Spotlight - Vijaya Jori

Date: 04/01/2022

Community Advisory Boards are key members of research programs. The ACTG Newsletter features Vijaya Jori of the JHU-BJGMC CAB!

This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...